Management Information Circular 2019
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry
The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry By: Maitri Punjabi Honors Thesis Economics Department The University of North Carolina at Chapel Hill March 2016 Approved: ______________________________ Dr. Jonathan Williams Punjabi 2 Abstract This paper analyzes the effect of the changing nature of innovation on pharmaceutical firm market value from the years 1987 to 2010 by using U.S. patent and claim data. Over the years, firms have started shifting focus from primary innovation to secondary innovation as new ideas and new compounds become more difficult to generate. In this study, we analyze the impact of this patent portfolio shift on the market capitalization of pharmaceutical firms. After using firm fixed effects and the instrumental variable approach, we find that there exists a strong positive relationship between secondary innovations and the market value of the firm– in fact, we find a stronger relationship than is observed between primary innovation and market value. When focusing on the different levels of innovation within the industry, we find that this relationship is stronger for less-innovative firms (those that have produced fewer patents) than it is for highly- innovative firms. We also find that this relationship is stronger for firms that spend less on research and development, complementing earlier findings that research productivity is declining over time. Punjabi 3 Acknowledgements I would primarily like to thank my adviser, Dr. Jonathan Williams, for his patience and constant support. Without his kind and helpful attitude, this project would have been a much more frustrating process. Through his knowledge of the industry, I have gained valuable insight and have learned a great deal about a unique and growing field. -
United States Securities and Exchange Commission Form 10-K Shire Pharmaceuticals Group
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ፤ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 1999 អ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PHARMACEUTICALS GROUP PLC (Exact name of registrant as specified in its charter) England and Wales (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) N.A. East Anton, Andover, Hampshire SP10 5RG England (Address of principal executive offices) (Zip Code) 44 1264 333455 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depository Shares, each representing Nasdaq National Market 3 Ordinary Shares, 5 pence nominal value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ፤ No អ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference to Part III of this Form 10-K or any amendment to this Form 10-K. -
United States Securities and Exchange Commission Washington, D.C
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33500 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 98-1032470 (State or other jurisdiction of (I.R.S. Employer Identification incorporation or organization) No.) Fifth Floor, Waterloo Exchange Waterloo Road, Dublin 4, Ireland 011-353-1-634-7800 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on Title of each class which registered Ordinary shares, nominal The NASDAQ Stock Market value $0.0001 per share LLC Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. -
Consolidation Revisited Is the Founder of Managing Resources, a Date Received *In Revised Form) 8Th October, 2001 Consultancy Focused on the Life Science Industries
Alan Williams Consolidation revisited is the founder of Managing Resources, a Date received *in revised form) 8th October, 2001 consultancy focused on the life science industries. The Alan Williams company undertakes strategic assignments and also assists public and private sector clients with regulatory affairs, investor Abstract In 1998, the author produced two papers that argued that consolidation was relations and human a necessary activity for biotechnology companies to pay greater attention to. Three resources development. years later a further consideration of the subject seems worthwhile. Examples of Alan has also been an investment manager in successful consolidators are reviewed. a venture capital company, and held Keywords: consolidation, mergers, acquisitions marketing and licensing positions in Fisons. Introduction drink, vaccines and animal health but there is now greater focus on the highest In the early/mid-1970s, the pharmaceutical pro®tability sector, human pharmaceuticals. industry consisted of more than 100 At the time of writing, GSK is rumoured to research-based businesses of some be a possible purchaser of Bayer's signi®cant size, although none of them pharmaceutical business, the future of could convincingly claim a global presence. which has been questioned after the Typically, a leading company had a strong withdrawal of cerivastatin. position in its local market "examples Aventis, the eighth largest pharmaceutical included Merck and P®zer in the USA, company by sales in 2000,1 includes the Bayer in Germany, Beecham in the UK, operations of 1970s companies such as Roussel-Uclaf in France and Fujisawa in Rhone-Poulenc, Rorer, Fisons, Hoechst, Japan) and possibly some other Marion, Richardson Merrell, and some neighbouring countries "US companies in smaller companies. -
Shire: a Focused Global Pharmaceutical Company Focusing on a Bright Future Shire Pharmaceuticals Group Plc the Shire Mission
Shire Pharmaceuticals Group plc Annual review and summary financial statement 2003 Shire: a focused global pharmaceutical company Focusing on a bright future Shire Pharmaceuticals Group plc The Shire mission Our mission is to become the leading company in meeting the needs of the specialist physician. We want to achieve this by developing and Contents 01 Financial highlights marketing products of the highest quality 02 Chairman’s statement 04 Chief Executive Officer’s review for the treatment of serious diseases, 06 Product portfolio 07 Product development pipeline which are treated by medical specialists. 08 Operating review 22 CSR: Corporate and social responsibility 24 Financial review We aim to provide high quality and effective 28 Board of Directors 30 The Executive Committee products that enhance the health and 32 Directors’ remuneration report 44 Corporate governance quality of life of people around the world statement Financial Statements and contribute to the long-term business 48 Statement of Directors’ responsibilities – Report of success of our Company, to the benefit independent auditors 49 Consolidated balance sheets 50 Consolidated statement of all our stakeholders. of operations 51 Consolidated statements of changes in shareholders’ equity We are driven by the needs of all our 52 Consolidated statements of cash flows stakeholders: patients, their families and 53 Notes to the consolidated financial statements 87 Five-year review caregivers, doctors and medical specialists, 88 Summary financial statement 93 Notes to summary employees and partner companies, the financial statement community in which we live and work and, Other 94 Shire head office and main operating locations of course, our shareholders. -
Stage New Drug Discovery
Public Support for Late- Stage New Drug Discovery The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Nayak, Rahul K. 2019. Public Support for Late-Stage New Drug Discovery. Doctoral dissertation, Harvard Medical School. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:41971479 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Scholarly Report submitted in partial fulfillment of the MD Degree at Harvard Medical School Date: 27 March 2019 Student Name: Rahul K Nayak, BSE Scholarly Report Title: Public support for late-stage new drug discovery Mentor Name(s) and Affiliations: Aaron S. Kesselheim, MD, JD, MPH, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA Collaborators, with Affiliations: Jerry Avorn, MD, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 1 Abstract Title: Public support for late-stage new drug discovery Rahul K Nayak, Jerry Avorn, Aaron S. Kesselheim Purpose: To determine the role of publicly-supported research in the development of innovative new medications. Method: We examined patent data and drug discovery and development histories to assess the extent of public support for late-stage medication development for all new drugs approved by the US Food and Drug Administration (FDA) containing one or more new molecular entity approved between January 2008 and December 2017 via the new drug application pathway. -
Inkforgelaunchhandbook.Pdf
Early Career Researchers.. In hosting this event we would like to say thank you to our industrial partners, who have helped us to shape this program so far. You have done this with dispassionate honesty and enthusiasm, which has been most welcome and encouraging to us all. It has been a steep learning curve for us and we know this is only the beginning. Be reassured that we appreciate the time you are giving and we value hearing your advice and your requests. We may not always get it right but we are genuinely committed to nurturing this partner- ship in a mutually beneficial way that will create a ‟culture of interaction with industry‟ in our institution. Our aim is that the next generation of research leaders will be able to thrive through collaboration, and will be a testament to those who dedicated time to their training. To the academic staff and early career researchers, we would like to encourage you to take up this unique opportunity to increase your network of industrial partners, let them know your strengths and discover their needs. We are entering a new era in the history of universities and the opportunity to network with industrial partners will enable us to en- hance the impact of our research. To those in management positions, we invite you to en- gage with our help in building the InKForge portfolio of events within departments . We hope you will ensure that the early career researchers working with you take part in this process and have the opportunity to learn how it is done. -
Annual Report on Form 20-F 2009
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ‘ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 OR ‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ‘ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report ................... For the transition period from to Commission File Number: 001-31368 Sanofi-Aventis (Exact name of registrant as specified in its charter) N/A (Translation of registrant’s name into English) France (Jurisdiction of incorporation or organization) 174, avenue de France, 75013 Paris, France (Address of principal executive offices) Karen Linehan, Senior Vice President Legal Affairs and General Counsel 174, avenue de France, 75013 Paris, France. Fax: 011 + 33 1 53 77 43 03 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Name of each exchange Title of each class: on which registered: American Depositary Shares, each New York Stock Exchange representing one half of one ordinary share, par value €2 per share Ordinary shares, par value €2 per share New York Stock Exchange (for listing purposes only) Securities registered pursuant to Section 12(g) of the Act: American Depositary Shares, each representing one quarter of a Participating Share Series A, par value €70.89 per share (removed from listing and registration on the New York Stock Exchange effective July 31, 1995). -
FTSE 100 Historic Additions and Deletions
FTSE 100 Historic Additions and Deletions ftserussell.com An LSEG Business September 2021 FTSE 100 – Historic Additions and Deletions Date Added Deleted Notes 19-Jan-84 Charterhouse J Rothschild Eagle Star Corporate Event - Acquisition of Eagle Star by BAT Industries 02-Apr-84 Lonrho Magnet & Southerns 02-Jul-84 Reuters Edinburgh Investment Trust 02-Jul-84 Woolworths Barratt Development 19-Jul-84 Enterprise Oil Bowater Corporation Corporate Event - Sub division of company into Bowater Inds and Bowater Inc 01-Oct-84 Willis Faber Wimpey (George) & Co 01-Oct-84 Granada Group Scottish & Newcastle Breweries 01-Oct-84 Dowty Group MFI Furniture Corporate Event - Acquisition of MFI Furniture by Associated Dairies Group 04-Dec-84 British Telecom Johnson Matthey Fast Entry 02-Jan-85 Dee Corporation Dowty Group 02-Jan-85 Argyll Group Berisford (S & W) 02-Jan-85 MFI Furniture RMC Group 02-Jan-85 Dixons Group Dalgety 01-Feb-85 Jaguar Hambro Life Corporate Event - Acquisition of Hambro Life by BAT Industries 01-Apr-85 Guinness (Arthur) & Son Enterprise Oil 01-Apr-85 Smith Industries House of Fraser Corporate Event - Acquisition of House of Fraser by Alfayed Investment Trust 01-Apr-85 Ranks Hovis McDougall MFI Furniture Corporate Event - Acquisition of MFI Furniture by Associated Dairies Group 01-Jul-85 Abbey Life Ranks Hovis McDougall 01-Jul-85 Debenhams Imperial Continental Gas Ass. 06-Aug-85 Bank of Scotland Debenhams 01-Oct-85 Habitat Mothercare Lonrho 02-Jan-86 Scottish & Newcastle Rothschild (J) Holdings 08-Jan-86 Storehouse Habitat Mothercare -
Celltech Group Plc Annual Report and Accounts 2003
Celltech Group plc Annual Report and Accounts 2003 Celltech is a leading European complementary capabilities through biotechnology company with a long-term collaborations with other pharma and commitment to the research and biotech companies.This strategy, development of innovative therapies for supported by its strong revenue stream, patients with serious diseases.Celltech is enables Celltech to maintain a substantial a recognised global leader in advanced investment in research and development antibody technologies, which together whilst maintaining its financial strength with its innovative small molecule and flexibility. capabilities, provide a strong platform for Corporate Statement development of first-in-class or best-in- The combination of these strengths class treatments for immune and underpins Celltech’s goal of becoming a inflammatory disorders and cancer. global biotechnology leader, which will be furthered by the successful Celltech is focused on maximising value development and commercialisation of its from its products by marketing its own key late-stage development product, products to specialist prescribers through CDP870, and by the rapid progression of its extensive US and European its promising early-stage pipeline commercial operations and by accessing products. 1 Chairman’s Statement 2 Chief Executive’s Statement 3 2003 Highlights 4 Development Portfolio Contents 6 Operational Review – Research and Development 14 Operational Review – Global Commercial 18 Financial Review 24 Board of Directors 26 Directors’ Report -
Jazz Pharmaceuticals Plc Proxy Statement 2018 Annual Report Proxy Statement — 2018 Annual Report June 14, 2019
Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc Proxy Statement 2018 Annual Report Proxy Statement — 2018 Annual Report Proxy June 14, 2019 DEAR SHAREHOLDERS, Over the last year, Jazz Pharmaceuticals has continued to deliver life-changing medicines to patients across the world. With four globally marketed products, more than 20 active or planned research and development programs across two key therapeutic areas and access to three innovative platform technologies, the company is well positioned for sustainable long-term growth. In the past five years, we generated approximately $3 billion in cash from operations, allowing us to invest significantly in R&D and corporate development transactions to diversify and expand our commercial and development portfolios with differentiated products and product candidates. In our sleep therapeutic area, we remain dedicated to MEET JACKIE expanding available options for patients suffering from chronic and debilitating sleep disorders. In 2018 and early 2019, our Our patient story highlights Jackie. significant accomplishments included: In 2002, Jackie was diagnosed with obstructive • U.S. Food and Drug Administration (FDA) approval of sleep apnea (OSA), a highly prevalent disease in which Xyrem® (sodium oxybate) oral solution for the treatment of excessive daytime sleepiness (EDS) is a major presenting cataplexy or excessive daytime sleepiness (EDS) in children complaint. EDS can negatively impact the lives of people and adolescents with narcolepsy. Narcolepsy is often living with OSA at work, at home or in daily activities. underdiagnosed, especially in children, and we are pleased Xyrem is now available for narcolepsy patients seven years Prior to her diagnosis, Jackie was working full-time as a nurse practitioner while raising four children with her of age and older. -
Jazz Pharmaceuticals Plc Proxy Statement 2017 Annual Report
Proxy Statement Proxy 2017 Annual Report Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc Proxy Statement — 2017 Annual Report June 15, 2018 Dear Shareholders, Over the past six years, Jazz Pharmaceuticals has evolved into an integrated global biopharmaceutical company, with deep therapeutic expertise in serious sleep disorders and hematology/oncology-related diseases. During this time, we have deployed approximately $4 billion in capital to meaningfully diversify our business, received multiple global regulatory approvals and launched two new hematology/oncology products, while making significant advancements in multiple R&D programs. Our commitment to investing in new, innovative therapeutic options for patients while driving long-term, Meet John sustainable growth for our shareholders has remained unwavering and was demonstrated by our pivotal Our cover highlights John. After working achievements in 2017. in the steel industry for 45 years, John retired in 2009 and, with his wife Cherie, In 2017, we received marketing authorization for and began traveling the world visiting family successfully launched Vyxeos® (daunorubicin and and friends and seeking new adventures. cytarabine) liposome for injection in the U.S., the first In 2013, John noticed changes in his new chemotherapy advance in more than 40 years for health. He was fatigued, bruised easily and adults with certain types of high-risk AML. We also was not his usual energetic self. Shortly announced positive results from our three Phase 3 studies thereafter, John was diagnosed with of solriamfetol for the treatment of excessive sleepiness acute myeloid leukemia, or AML, a rapidly (ES) in narcolepsy and obstructive sleep apnea (OSA) progressing and life-threatening blood and from our Phase 2/3 study of Xyrem® (sodium cancer.